$RYTM News
Last published 2d ago
- 2d agoRYTMGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - RHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsGreat. Well, good morning, everyone, and thanks for joining us today here for another of Guggenheim's annual conferences, our Healthcare Innovation Conference 2026. To my left is the CEO and President and Chairman of Rhy
- 1w agoRYTMRhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl SyndromeGlobeNewswire-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc.
- 1w agoRYTMRHYTHM PHARMACEUTICALS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoRYTMRhythm Pharmaceuticals Q3 2026 Earnings Conference Call - RHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to Rhythm Pharmaceutical's third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation,
- 1w agoRYTMRhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business UpdateGlobeNewswire-- Strong U.S. launch momentum for IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 ---- Third quarter 2026 net product revenue
- 1w agoRYTMKKRRhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License AgreementGlobeNewswire-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed
- 3w agoRYTMRhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026GlobeNewswireBOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 4w agoRYTMRhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityGlobeNewswire-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients
- 1mo agoRYTMKuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ:...
- 1mo agoRYTMMorgan Stanley 24th Annual Global Healthcare Conference - RHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsAll right, good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Galtz. We're the biotech analysts here, and it's my pleasure to introduce David Meeker, Presiden
- 1mo agoRYTMMorgan Stanley 24th Annual Global Healthcare Conference - RHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsAll right, good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Galtz. We're the biotech analysts here, and it's my pleasure to introduce David Meeker, Presiden
- 1mo agoRYTMRhythm - 1773827 - RHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsAll right, good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Galtz. We're the biotech analysts here, and it's my pleasure to introduce David Meeker, Presiden
- 2mo agoRYTMRhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology MeetingGlobeNewswire-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements
- 2mo agoRYTMRhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in JapanGlobeNewswire-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- BOSTON, Aug. 24, 2026
- 2mo agoRYTMRhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical OfficerGlobeNewswireBOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 3mo agoRYTMCG 46TH ANNUAL GROWTH CONFERENCE - RHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, everyone, again. Thanks for joining us. I'm Whitney Egyem, one of the biotech analysts here at Canaccord, and it is my pleasure to be hosting Rhythm Pharmaceuticals this morning for this fireside chat. We w
- 3mo agoRYTMCG 46TH ANNUAL GROWTH CONFERENCE - RHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, everyone, again. Thanks for joining us. I'm Whitney Egyem, one of the biotech analysts here at Canaccord, and it is my pleasure to be hosting Rhythm Pharmaceuticals this morning for this fireside chat. We w
- 3mo agoRYTMRhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or ImpairmentGlobeNewswireBOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 3mo agoRYTMRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesGlobeNewswireBOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 3mo agoRYTMRhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business UpdateGlobeNewswire-- U.S. launch of IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 ---- Second quarter 2026 net product revenue
- 3mo agoRYTMRhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic ObesityGlobeNewswire-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon -- -- Management to host conference call to discuss second quarter 2026 financial
- 3mo agoRYTMKuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ:...
- 3mo agoRYTMRhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026GlobeNewswireBOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 3mo agoRYTMKuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmGlobeNewswireNEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) breached their
- 4mo agoRYTMRhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic ObesityGlobeNewswireBOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 5mo agoRYTMResults from Phase 2 Trial Evaluating Setmelanotide in PWS at Six Months - Rythm PharmaEarnings Call TranscriptsGood day everyone and thank you for standing by. Welcome to Rhythm Pharmaceuticals results from phase two Prader-Willi syndrome trial. At this time all participants are in a listen-only mode. After the speaker's presenta
- 5mo agoRYTMRhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026GlobeNewswire-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and
- 5mo agoRYTMRhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi SyndromeGlobeNewswireBOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 5mo agoRYTMRhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026GlobeNewswireBOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 5mo agoRYTMRhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical GeneticsGlobeNewswireBOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 5mo agoRYTMRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesGlobeNewswireBOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 6mo agoRYTM2026 GLOBAL HEALTHCARE CONFERENCERHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsOkay. Good afternoon. Welcome back to the Bank of America Healthcare Conference. I'm Tazina Mott. I am one of the senior biotech analysts here at the bank. It's my pleasure to have our next presenting company, Rhythm Pha
- 6mo agoRYTMRhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of EndocrinologyGlobeNewswire– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France – – Phase 3 analyses demonstrated improvements
- 6mo agoRYTMRhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare ConferenceGlobeNewswireBOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 6mo agoRYTMRhythm Pharmaceuticals Q1 2026 Earnings Conference Call - RHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by and welcome to the Rhythm Pharmaceuticals first quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's present
- 6mo agoRYTMRhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateGlobeNewswire-- IMCIVREE® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- First quarter
- 6mo agoRYTMRhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine SocietyGlobeNewswire-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy ---- Weight category improvements observed in pediatric patients with
- 6mo agoRYTMRhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic ObesityGlobeNewswire-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity
- 7mo agoRYTMRhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026GlobeNewswireBOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 7mo agoRYTMRhythm Pharmaceuticals Announces Changes to Board of DirectorsGlobeNewswire-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on
- 7mo agoRYTMRhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or ImpairmentGlobeNewswire-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company
- 7mo agoRYTMPANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)PR NewswirePANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that...
- 8mo agoRYTMRhythm Pharmaceuticals Conference Call - RHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals conference call. At this time all participants are in a listen-only mode. After the speaker's presentation there will be a question and answer
- 8mo agoRYTMRhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE TrialGlobeNewswire-- Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heterozygous variant of the
- 8mo agoRYTMRhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic ObesityGlobeNewswire-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20,
- 8mo agoRYTMRhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business UpdateGlobeNewswire-- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity (HO) ----
- 8mo agoRYTMRhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026GlobeNewswireBOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 9mo agoRYTMRhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech SummitGlobeNewswireBOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine
- 10mo agoRYTMRhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming MilestonesGlobeNewswire-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net
- 11mo agoRYTMRhythm Pharmaceuticals Conference Call - RHYTHM PHARMACEUTICALS INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to Rhythm Pharmaceuticals conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and